Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-509 in Diabetic Neuropathy
NCT00406458Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Nov 2006
- Primary completion
- Dec 2008
- Modality
- Gene Silencing, Plasmid DNA, Zinc Finger Nucleases
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of SB-509 in diabetic polyneuropathy (DPN) (2 arms), sponsored by Sangamo Therapeutics. Primary endpoints: Visual Analog Scale for Pain Intensity at 1 year, Nerve Conduction Velocity at 1 year and 3 more. Started Nov 2006; status: completed.
02
Drugs
SB-509
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT00406458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406458.